Beta-2 microglobulin is a small protein found on the surface of most cells in the body. A blood test for beta-2 microglobulin, often shortened to B2M or β2M, measures how much of this protein is circulating in your bloodstream. Higher levels can appear when the kidneys are not clearing B2M well, when certain immune cells are very active, or when blood and bone marrow cancers such as multiple myeloma, lymphoma, or chronic lymphocytic leukemia are being monitored.
This test is not a general cancer screening test. A high result does not diagnose cancer by itself, and it does not point to one single disease. Its value comes from context: kidney function tests, urine findings, blood counts, protein studies, symptoms, and whether someone already has a known blood cancer. In the right setting, B2M can help estimate disease burden, monitor treatment response, and flag kidney-related concerns that deserve follow-up.
- Beta-2 microglobulin mainly reflects kidney clearance, immune cell activity, and tumor burden in some blood cancers.
- A typical adult serum reference range is roughly 0.6–2.7 mg/L, but each lab’s range should be used.
- High B2M can occur with kidney disease, inflammation, infections, autoimmune disease, multiple myeloma, lymphoma, and CLL.
- B2M is not specific enough to diagnose cancer, kidney disease, or autoimmune disease on its own.
- Urine B2M is more focused on kidney tubule injury, while blood B2M rises when kidney filtration is reduced or cell turnover is increased.
- Urgent follow-up matters if high B2M appears with kidney failure signs, severe bone pain, anemia, high calcium, unexplained weight loss, or abnormal blood counts.
Table of Contents
- What Beta-2 Microglobulin Measures
- When the Beta-2 Microglobulin Test Is Ordered
- Normal Range, Units, and How to Read the Number
- High Beta-2 Microglobulin Results
- Kidney Function, Urine B2M, and Tubular Damage
- Beta-2 Microglobulin as a Blood Cancer Marker
- Low Results, False Signals, and Test Limitations
- Next Steps After an Abnormal B2M Result
What Beta-2 Microglobulin Measures
Beta-2 microglobulin is part of a normal immune-related structure called major histocompatibility complex class I, or MHC class I. These structures sit on the surface of almost all nucleated cells, meaning nearly all body cells except mature red blood cells. As cells naturally turn over, small amounts of B2M enter the blood.
The kidneys remove much of this circulating B2M. It is freely filtered through the glomeruli, the tiny filtering units of the kidney, and then mostly reabsorbed and broken down by the proximal tubules. Because of this pathway, B2M sits at the intersection of two different issues:
- Production: More B2M may be released when immune cells or cancerous blood cells are more active.
- Clearance: More B2M may remain in the blood when kidney filtration is reduced.
- Tubular handling: More B2M may spill into urine when the kidney tubules cannot reabsorb it properly.
That is why one B2M number rarely tells the whole story. A high blood level may come from lower kidney filtration, higher cell turnover, immune activation, or more than one of these at the same time.
For kidney evaluation, B2M is usually interpreted alongside eGFR results, serum creatinine, urine protein or albumin, and the person’s medical history. For blood cancer monitoring, it is usually interpreted with blood counts, imaging, bone marrow results, monoclonal protein tests, free light chains, lactate dehydrogenase, albumin, calcium, and kidney markers.
Blood B2M versus urine B2M
A blood beta-2 microglobulin test mainly reflects the amount of B2M in circulation. It is commonly used in blood cancer staging or monitoring and may also rise with kidney impairment.
A urine beta-2 microglobulin test focuses more on kidney tubule function. Under normal conditions, the kidney filters B2M and then reabsorbs almost all of it in the proximal tubules. When urine B2M is high, it can suggest tubular injury or impaired tubular reabsorption.
This distinction matters. A person with reduced glomerular filtration may have high blood B2M. A person with proximal tubule damage may have high urine B2M even when the blood result does not tell the full story.
When the Beta-2 Microglobulin Test Is Ordered
A beta-2 microglobulin test is usually ordered for a specific clinical reason, not as a routine wellness marker. It can be useful when a clinician is trying to understand kidney involvement, monitor a known blood cancer, or assess the activity of certain immune-related conditions.
Common reasons include:
- Staging or prognosis in multiple myeloma
- Monitoring some people with lymphoma or chronic lymphocytic leukemia
- Tracking treatment response in a known blood or bone marrow cancer
- Evaluating kidney involvement in multiple myeloma
- Looking for evidence of kidney tubule damage with urine B2M
- Assessing long-term dialysis-related B2M buildup in selected patients
- Supporting evaluation of immune activation in some autoimmune or inflammatory diseases
In multiple myeloma, B2M has a special role because it can reflect both tumor burden and kidney function. Myeloma can damage kidneys through monoclonal proteins, dehydration, high calcium, infections, and some medications. This makes B2M useful but also complicated: a high number may partly reflect myeloma activity and partly reflect reduced kidney clearance.
B2M may be ordered with a broader kidney or metabolic workup. A kidney function blood test panel often includes creatinine, eGFR, BUN, and electrolytes, while B2M adds a more specialized piece of information. It does not replace the standard kidney tests that clinicians use every day.
Symptoms and situations that may lead to testing
B2M may be part of the workup when someone has findings such as unexplained anemia, bone pain, recurrent infections, abnormal protein levels, enlarged lymph nodes, kidney dysfunction, or abnormal urine protein. It may also be checked after diagnosis to follow a known condition over time.
The test may be repeated at intervals when the trend is more important than one isolated value. In cancer monitoring, a falling B2M level after treatment may suggest response, while a rising level may suggest progression, relapse, kidney decline, or inflammation. The cause must be sorted out with other tests.
Normal Range, Units, and How to Read the Number
A common adult serum beta-2 microglobulin reference range is about 0.6–2.7 mg/L, though some laboratories use narrower or slightly different ranges. Mayo Clinic Laboratories lists a serum range of 1.21–2.70 mcg/mL, while Labcorp lists adult values of 0.6–2.4 mg/L. These units are directly comparable because 1 mcg/mL equals 1 mg/L.
Always use the reference interval printed next to your own result. B2M ranges vary by lab method, specimen type, age, and reporting unit. A result marked high by one lab may sit near the upper end of another lab’s range.
| Result pattern | Possible meaning | Common follow-up context |
|---|---|---|
| Within the lab range | No clear B2M elevation at that time | Still interpreted with symptoms, kidney tests, and cancer status |
| Mildly high | May reflect mild kidney impairment, inflammation, infection, immune activity, or early disease activity | Repeat testing and kidney markers may help clarify |
| Clearly high | More concerning for reduced clearance, active inflammatory disease, or higher blood cancer burden in the right setting | Usually reviewed with eGFR, creatinine, CBC, protein studies, and clinical findings |
| Rising over time | May suggest worsening kidney function, cancer progression, treatment resistance, or new inflammation | The trend is usually more useful than a single result |
| Falling over time | May suggest treatment response, improved kidney clearance, or reduced immune activation | Best interpreted with the condition being monitored |
Why a “normal” result does not always rule out disease
A normal B2M result is reassuring only for the question the test was meant to answer. It does not rule out kidney disease, lymphoma, multiple myeloma, CLL, autoimmune disease, or infection. Many conditions can be present with normal B2M, especially early in their course or when another marker is more sensitive.
For example, kidney disease is usually assessed first with eGFR and urine albumin. A person can have albumin in the urine with normal B2M. Another person can have reduced kidney filtration with a high B2M but minimal urine albumin. These patterns point to different parts of kidney physiology.
Why a high result does not diagnose cancer
B2M is a tumor marker only in a limited sense. It can help assess prognosis or treatment response in certain known cancers, especially blood and bone marrow cancers. It is not specific enough to diagnose cancer because kidney dysfunction, inflammation, viral infections, autoimmune disease, liver disease, and other noncancer conditions can also raise it.
This is one of the most common misunderstandings. A high B2M result means “look at the full picture,” not “this proves cancer.”
High Beta-2 Microglobulin Results
High beta-2 microglobulin means the blood level is above the reference range for that lab. The most common broad explanations are reduced kidney clearance, increased immune or cell turnover activity, or a blood cancer context where B2M reflects disease burden.
The degree of elevation matters, but context matters more. A mild elevation in someone with chronic kidney disease may have a different meaning from the same value in a person newly diagnosed with multiple myeloma. A rising level during cancer treatment may be more concerning than one stable mild elevation that matches long-standing kidney impairment.
Common causes of high B2M include:
- Chronic kidney disease
- Acute kidney injury
- Reduced kidney filtration from dehydration, obstruction, medication effects, or systemic illness
- Multiple myeloma
- Chronic lymphocytic leukemia
- Certain lymphomas
- Viral infections, including HIV in some settings
- Autoimmune diseases and chronic inflammatory conditions
- Liver disease or systemic inflammation
- Long-term dialysis with reduced removal of middle-molecule proteins
B2M is sometimes described as a “middle molecule” in dialysis because it is larger than small waste products such as urea. In people on long-term dialysis, B2M can accumulate and contribute to dialysis-related amyloidosis, a condition in which B2M deposits in tissues, especially around joints and bones.
High B2M with abnormal kidney markers
When B2M is high and creatinine is high or eGFR is low, kidney clearance becomes a major part of interpretation. The clinician will usually look at whether the kidney problem appears acute, chronic, or worsening.
Helpful companion tests may include:
- Creatinine and eGFR
- blood urea nitrogen
- Electrolytes such as potassium, bicarbonate, sodium, and chloride
- Urinalysis
- Urine albumin-to-creatinine ratio
- Urine protein-to-creatinine ratio
- Kidney ultrasound in selected cases
- Medication review for nephrotoxic drugs
In a person with suspected or known myeloma, kidney involvement needs careful attention because kidney function can worsen quickly. High calcium, dehydration, infection, nonsteroidal anti-inflammatory drugs, contrast dye, and monoclonal light chains can all strain the kidneys.
High B2M with normal creatinine
A high B2M with normal creatinine does not automatically mean the kidneys are normal. Creatinine can miss early or subtle changes, especially in people with low muscle mass. It also does not measure tubular reabsorption directly.
Other explanations also become more important when creatinine and eGFR look stable. These include inflammation, infection, autoimmune activity, or blood cell disorders. A complete blood count can help identify anemia, high lymphocytes, low platelets, or other clues that point toward a hematology evaluation.
Kidney Function, Urine B2M, and Tubular Damage
Beta-2 microglobulin can give different kidney information depending on whether it is measured in blood or urine. Blood B2M rises when kidney filtration falls because less B2M is cleared from the bloodstream. Urine B2M rises when the proximal tubules fail to reabsorb filtered B2M properly.
The proximal tubules are an early processing center inside each nephron. They reclaim filtered nutrients and small proteins, help balance acid and base, and handle substances such as glucose, amino acids, phosphate, bicarbonate, and small proteins. When these tubules are injured, B2M may appear in higher amounts in the urine.
Urine B2M may be used when clinicians suspect tubular damage from causes such as:
- Fanconi syndrome
- Interstitial nephritis
- Heavy metal exposure, especially cadmium or mercury
- Certain inherited kidney tubule disorders
- Some autoimmune diseases, including Sjögren disease
- Drug-related tubular injury
- Kidney transplant-related concerns in selected settings
- Tubular injury after acute kidney injury
Urine B2M is not the same as urine albumin. Albumin is a larger protein and often points more toward glomerular leakage, especially in diabetes, hypertension, and many forms of chronic kidney disease. B2M is a small protein and can point more toward proximal tubular reabsorption problems.
Sample handling is unusually important for urine B2M
Urine beta-2 microglobulin is unstable in acidic urine. If the urine pH is too low, B2M can break down and the result may look falsely low. Many laboratories require special collection instructions or preservatives to keep the urine pH in an acceptable range.
This detail is easy to overlook. A urine B2M result is only as useful as the specimen quality. If the result does not fit the clinical picture, clinicians may repeat the test or choose other tubular injury markers such as alpha-1 microglobulin, retinol-binding protein, kidney injury molecule-1, or NGAL, depending on availability and the clinical setting.
Blood B2M is not a replacement for eGFR
Although B2M is affected by kidney filtration, it is not the standard test used to stage chronic kidney disease. eGFR and urine albumin remain the usual foundation. B2M may add information in selected cases, but it should not replace conventional kidney assessment.
A practical way to think about it:
| Marker | Main role | What it can miss |
|---|---|---|
| Creatinine | Estimates kidney filtration through eGFR equations | Can be misleading with very low or high muscle mass |
| Cystatin C | Alternative filtration marker, often useful when creatinine is uncertain | Can be influenced by inflammation, thyroid disease, steroids, and other factors |
| Urine albumin | Detects kidney damage, especially glomerular leakage | Does not directly measure tubular reabsorption |
| Blood B2M | Reflects kidney clearance and cell turnover | Cannot separate kidney impairment from immune or cancer-related production by itself |
| Urine B2M | Helps evaluate proximal tubular dysfunction | Can be unreliable if urine pH and handling are not controlled |
When kidney function is uncertain, clinicians may add cystatin C testing or a measured clearance test, especially when drug dosing, chemotherapy decisions, or transplant evaluation depends on a more accurate estimate.
Beta-2 Microglobulin as a Blood Cancer Marker
Beta-2 microglobulin is most established as a prognostic and monitoring marker in certain blood and bone marrow cancers. It is especially important in multiple myeloma, where it forms part of the International Staging System.
In multiple myeloma, the International Staging System uses serum B2M and serum albumin:
- Stage I: B2M less than 3.5 mg/L and albumin 3.5 g/dL or higher
- Stage II: Neither stage I nor stage III
- Stage III: B2M greater than 5.5 mg/L
The Revised International Staging System adds other risk markers, including lactate dehydrogenase and high-risk chromosome changes found by specialized testing. This helps separate tumor burden, biological risk, and overall prognosis more clearly than B2M alone.
A high B2M in myeloma may reflect more myeloma cells, kidney impairment, or both. This is why B2M should be interpreted with creatinine, eGFR, albumin, calcium, hemoglobin, monoclonal protein level, serum free light chains, bone marrow findings, and imaging.
Lactate dehydrogenase can also be part of myeloma risk assessment, and a separate LDH blood test may be used when clinicians are looking for signs of more aggressive disease biology.
Multiple myeloma
In multiple myeloma, B2M is used mainly for staging, prognosis, and monitoring. A higher level at diagnosis is generally associated with higher disease burden or worse kidney clearance. During treatment, a falling B2M may support a favorable response, while a rising result may trigger a closer review for relapse, kidney decline, infection, or inflammation.
B2M is not the only marker followed in myeloma. Clinicians usually pay close attention to monoclonal protein, serum free light chains, kidney function, calcium, hemoglobin, bone lesions, and symptoms. A patient can improve in one marker while another marker needs attention.
Lymphoma and chronic lymphocytic leukemia
In some lymphomas and in chronic lymphocytic leukemia, B2M can provide prognostic information. Higher levels may be associated with greater disease activity or worse outcomes in some settings. However, kidney function still affects interpretation.
For example, a person with CLL and chronic kidney disease may have a higher B2M partly because the kidneys clear it less efficiently. That does not make the test useless, but it does mean clinicians should avoid reading it as a pure cancer signal.
Why trends matter more than one result
For cancer monitoring, the pattern over time often carries more meaning than a single number. A B2M result that falls after treatment, stays low during remission, or rises alongside other disease markers can help clinicians judge what is happening.
A single high value can be misleading if it was drawn during an infection, dehydration, acute kidney injury, or inflammatory flare. When the result does not match the rest of the picture, repeating the test after the temporary issue resolves may be more useful than reacting to one number alone.
Low Results, False Signals, and Test Limitations
Low beta-2 microglobulin is usually not a major medical concern. Most clinical attention goes to elevated levels or rising trends. If a result is below the reference range, it is often not meaningful unless the laboratory flags a specimen or technical issue.
The bigger issue is misinterpretation. B2M is a nonspecific marker, so it can send false signals when taken out of context. A high result can look alarming, but it may come from a noncancer cause. A normal result can look reassuring, but it does not rule out kidney disease, blood cancer, or autoimmune disease.
Important limitations include:
- Kidney function strongly affects blood B2M. Reduced clearance can raise the level even without cancer progression.
- Inflammation can raise B2M. Autoimmune disease, infection, and immune activation can increase production.
- Assay methods differ. Results from different laboratories may not be perfectly interchangeable.
- Urine handling matters. Acidic urine can degrade B2M and produce a falsely low urine result.
- B2M is not a screening test. It is most useful when the clinician already has a focused question.
- Trends need stable conditions. Comparing results is most helpful when kidney function, infection status, and lab method are considered.
A common mistake is comparing results across different labs without checking units and reference ranges. Another is assuming that a value above the range has the same meaning for everyone. A B2M of 4 mg/L may be interpreted differently in a person with stable chronic kidney disease than in a person with newly diagnosed myeloma and normal baseline kidney function.
Medication and illness effects
B2M itself is not usually treated directly. Instead, clinicians address the underlying cause. Temporary illnesses can influence the result, especially if they affect inflammation, hydration, or kidney function.
Recent infection, severe inflammation, dehydration, contrast exposure, kidney-toxic medications, and acute illness can all change the setting in which B2M is interpreted. If the result was drawn during an unstable period, repeating it later may give a clearer picture.
Next Steps After an Abnormal B2M Result
An abnormal beta-2 microglobulin result should be followed by a focused review of why the test was ordered. The same number can mean different things depending on whether the concern is kidney function, myeloma staging, lymphoma monitoring, CLL prognosis, or tubular injury.
Useful next steps often include:
- Confirm the specimen and units. Check whether the result is blood, urine, or CSF, and whether it is reported in mg/L, mcg/mL, mcg/L, or another unit.
- Compare with the lab’s reference range. Do not rely only on a generic normal range.
- Review kidney markers. Creatinine, eGFR, BUN, electrolytes, and urine albumin or protein help clarify clearance and kidney damage.
- Look for temporary causes. Recent infection, dehydration, inflammation, or acute kidney injury can raise B2M.
- Check blood and cancer-related markers when relevant. CBC, albumin, calcium, LDH, monoclonal protein testing, and serum free light chains may be needed in suspected or known blood cancers.
- Interpret trends carefully. Repeat values from the same lab are often more useful than one isolated result.
Seek prompt medical attention if high B2M appears with symptoms or findings that suggest serious kidney or blood problems. These include markedly reduced urination, swelling, shortness of breath, confusion, severe weakness, chest pain, persistent vomiting, severe dehydration, new severe bone pain, unexplained fractures, very high calcium, rapidly worsening anemia, or abnormal bleeding.
For someone already diagnosed with multiple myeloma, lymphoma, or CLL, a rising B2M should be discussed with the treating hematology or oncology team. It may reflect disease activity, but it may also reflect kidney changes or another medical stressor. Treatment decisions should not be based on B2M alone.
For someone without a cancer diagnosis, a high B2M usually leads first to broader evaluation rather than immediate conclusions. Kidney function testing, urine testing, a CBC, inflammatory markers, infection assessment, medication review, and symptom-based follow-up are often more informative than repeating B2M alone.
Questions to ask your clinician
These questions can make the result easier to understand:
- Was my B2M measured in blood, urine, or another body fluid?
- Is the result mildly high or clearly high for this laboratory?
- Are my creatinine, eGFR, BUN, and urine protein results normal?
- Could recent infection, inflammation, dehydration, or medication use explain the result?
- Is this being used for kidney evaluation, cancer monitoring, or both?
- Should the test be repeated, and should it be repeated at the same lab?
- Which other results are most important for interpreting this number?
B2M works best as one piece of a pattern. The safest interpretation comes from matching the number to kidney function, immune activity, blood counts, cancer status, symptoms, and changes over time.
References
- Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Medical Test 2025 (Official Medical Test Information)
- B2M – Overview: Beta-2-Microglobulin, Serum 2025 (Laboratory Reference)
- B2MU – Overview: Beta-2 Microglobulin, Random, Urine 2025 (Laboratory Reference)
- Renal Function Tests 2024 (Review)
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management 2024 (Review)
- ISS & R-ISS Staging for Multiple Myeloma: Complete Guide 2026 (Official Organization Resource)
Disclaimer
Beta-2 microglobulin results should be interpreted by a qualified healthcare professional who can review your kidney function, blood counts, symptoms, medications, and medical history. A high result does not diagnose cancer, kidney disease, or autoimmune disease by itself. Seek urgent care for severe weakness, confusion, reduced urination, chest pain, shortness of breath, severe dehydration, abnormal bleeding, or sudden severe bone pain.
